Patch/plaque mycosis‐fungoides‐like presentations of <i><scp>DUSP22</scp>‐</i>translocated T‐cell lymphomas

Runge, John S.; Novice, Madison; Briones, Naomi F.; Williams, Kristen; Lowe, Lori; Boyer, Daniel F.; Wilcox, Ryan A.; Tejasvi, Trilokraj; Hristov, Alexandra C.

doi:10.1111/cup.14156

Cited by 6 publications

(2 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A new LyP subtype was recently identified, characterised by a rearrangement of DUSP22 and IRF4 (Interferon Regulatory Factor 4), a tumour suppressor gene regulating T-cell proliferation, at the 6p25.3 locus; the same rearrangements have been previously reported in pcALCL, where they are observed in 20-57% of cases [37]. DUSP22-IRF4 gene rearrangement has also been described in systemic ALCL and transformed MF [38].…”

Section: Genetics Of Primary Cutaneous Cd30-positive Lymphoproliferat...mentioning

confidence: 58%

Primary Cutaneous CD30-Positive Lymphoproliferative Disorders—Current Therapeutic Approaches with a Focus on Brentuximab Vedotin

Stein,

Robak,

Biernat

et al. 2024

JCM

View full text Add to dashboard Cite

One of the most common subgroups of cutaneous T-cell lymphomas is that of primary cutaneous CD30-positive lymphoproliferative disorders. The group includes lymphomatoid papulosis (LyP) and primary cutaneous anaplastic large cell lymphoma (pcALCL), as well as some borderline cases. Recently, significant progress has been made in understanding the genetics and treatment of these disorders. This review article summarises the clinical evidence supporting the current treatment options for these diseases. Recent years have seen the introduction of novel agents into clinical practice; most of these target CD30, such as anti-CD30 monoclonal antibodies and conjugated antibodies (brentuximab vedotin), bispecific antibodies and cellular therapies, particularly anti-CD30 CAR-T cells. This paper briefly reviews the biology of CD30 that makes it a good therapeutic target and describes the anti-CD30 therapies that have emerged to date.

show abstract

Section: Genetics Of Primary Cutaneous Cd30-positive Lymphoproliferat...mentioning

confidence: 58%

Primary Cutaneous CD30-Positive Lymphoproliferative Disorders—Current Therapeutic Approaches with a Focus on Brentuximab Vedotin

Stein,

Robak,

Biernat

et al. 2024

JCM

View full text Add to dashboard Cite

show abstract

“…Albeit rarely, the presence of DUSP22–IRF4 rearrangement has also been previously documented in transformed MF 7 . More recently, rare cases of patch/plaque MF‐like lesions without definitive large cell transformation harboring DUSP22 translocation 10 and DUSP22 ‐rearranged primary cutaneous T‐cell lymphoma with features intermediate between MF, ALCL, and LyP 11 have also been reported, thus expanding the spectrum of DUSP22–IRF4 ‐rearranged LPDs involving the skin. The latter report was not included in our literature review of LyP with DUSP22–IRF4 rearrangement, with our intention to only include cases with “pure” DUSP22 ‐rearranged LyP.…”

Section: Discussionmentioning

confidence: 89%

Lymphomatoid papulosis with DUSP22–IRF4 rearrangement: A case report and literature review

et al. 2023

View full text Add to dashboard Cite

Lymphomatoid papulosis (LyP) with DUSP22–IRF4 rearrangement is a rare, recently described variant of LyP histopathologically characterized by a biphasic growth pattern, with epidermotropic small‐to‐medium‐sized atypical T‐cells and dermal large and transformed T‐cells diffusely expressing CD30. LyP with DUSP22–IRF4 rearrangement can mimic other cutaneous lymphoproliferative disorders, particularly primary cutaneous anaplastic large cell lymphoma (PCALCL) or transformed mycosis fungoides (MF). Unlike PCALCL or transformed MF, LyP with DUSP22–IRF4 rearrangement shows an indolent clinical behavior, with frequent spontaneous regression of untreated lesions. Thus, it is important to recognize this rare variant of LyP to avoid misclassification, which may potentially lead to unnecessarily aggressive patient management. To our knowledge, only 13 cases of LyP with DUSP22–IRF4 rearrangement have been reported to date in the English literature. Herein, we describe an additional case of LyP with DUSP22–IRF4 rearrangement in a 63‐year‐old man and provide a comprehensive literature review with regards to the clinical, histopathologic, and molecular features of this novel entity.

show abstract

Primary cutaneous T-cell lymphoma: a review of the most common entities with focus on recent updates

2023

View full text Add to dashboard Cite

Patch/plaque mycosis‐fungoides‐like presentations of DUSP22‐translocated T‐cell lymphomas

Cited by 6 publications

References 21 publications

Primary Cutaneous CD30-Positive Lymphoproliferative Disorders—Current Therapeutic Approaches with a Focus on Brentuximab Vedotin

Primary Cutaneous CD30-Positive Lymphoproliferative Disorders—Current Therapeutic Approaches with a Focus on Brentuximab Vedotin

Lymphomatoid papulosis with DUSP22–IRF4 rearrangement: A case report and literature review

Primary cutaneous T-cell lymphoma: a review of the most common entities with focus on recent updates

Contact Info

Product

Resources

About